Paul Nguewa-rekin lankidetzan egindako argitalpenak (14)

2024

  1. Promising aryl selenoate derivatives as antileishmanial agents and their effects on gene expression

    Antimicrobial Agents and Chemotherapy, Vol. 68, Núm. 4

  2. Structure and activity of amphiphilic PEO-PPO-based polymeric micelles and gels incorporating host–guest complexes of miltefosine as novel formulations for the treatment of leishmaniasis

    Journal of Molecular Liquids, Vol. 400

2022

  1. Repurposing the Antibacterial Agents Peptide 19-4LF and Peptide 19-2.5 for Treatment of Cutaneous Leishmaniasis

    Pharmaceutics, Vol. 14, Núm. 11

2019

  1. Leishmanicidal activity of isoselenocyanate derivatives

    Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 2

2018

  1. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions

    Journal of Dermatological Science, Vol. 92, Núm. 1, pp. 78-88

2016

  1. Novel heteroaryl selenocyanates and diselenides as potent antileishmanial agents

    Antimicrobial Agents and Chemotherapy, Vol. 60, Núm. 6, pp. 3802-3812

2015

  1. Leishmanicidal activities of novel methylseleno-imidocarbamates

    Antimicrobial Agents and Chemotherapy, Vol. 59, Núm. 9, pp. 5705-5713

2014

  1. Nanoparticles as multifunctional devices for the topical treatment of cutaneous leishmaniasis

    Expert Opinion on Drug Delivery, Vol. 11, Núm. 4, pp. 579-597

  2. Novel hybrid selenosulfonamides as potent antileishmanial agents

    European Journal of Medicinal Chemistry, Vol. 74, pp. 116-123

  3. Thermosensitive hydrogels of poly(methyl vinyl ether-co-maleic anhydride) - Pluronic® F127 copolymers for controlled protein release

    International Journal of Pharmaceutics, Vol. 459, Núm. 1-2, pp. 1-9

  4. Topical treatment of L. major infected BALB/c mice with a novel diselenide chitosan hydrogel formulation

    European Journal of Pharmaceutical Sciences, Vol. 62, pp. 309-316

2012

  1. Innovative lead compounds and formulation strategies as newer kinetoplastid therapies

    Current Medicinal Chemistry, Vol. 19, Núm. 25, pp. 4259-4288

  2. Structure- and cell-specific effects of imidoselenocarbamates on selenoprotein expression and activity in liver cells in culture

    Metallomics, Vol. 4, Núm. 12, pp. 1297-1307

  3. The quinoline imidoselenocarbamate EI201 blocks the AKT/mTOR pathway and targets cancer stem cells leading to a strong antitumor activity

    Current Medicinal Chemistry, Vol. 19, Núm. 18, pp. 3031-3043